Cargando…
Blood Biomarkers from Research Use to Clinical Practice: What Must Be Done? A Report from the EU/US CTAD Task Force
Timely and accurate diagnosis of Alzheimer’s disease (AD) in clinical practice remains challenging. PET and CSF biomarkers are the most widely used biomarkers to aid diagnosis in clinical research but present limitations for clinical practice (i.e., cost, accessibility). Emerging blood-based markers...
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9683846/ https://www.ncbi.nlm.nih.gov/pubmed/36281661 http://dx.doi.org/10.14283/jpad.2022.85 |
| _version_ | 1784835142974439424 |
|---|---|
| author | Angioni, D. Delrieu, J. Hansson, O. Fillit, H. Aisen, P. Cummings, J. Sims, J.R. Braunstein, J.B. Sabbagh, M. Bittner, T. Pontecorvo, M. Bozeat, S. Dage, J.L. Largent, E. Mattke, S. Correa, O. Robledo, L.M. Gutierrez Baldivieso, V. Willis, D.R. Atri, A. Bateman, R.J. Ousset, P-J. Vellas, B. Weiner, M. |
| author_facet | Angioni, D. Delrieu, J. Hansson, O. Fillit, H. Aisen, P. Cummings, J. Sims, J.R. Braunstein, J.B. Sabbagh, M. Bittner, T. Pontecorvo, M. Bozeat, S. Dage, J.L. Largent, E. Mattke, S. Correa, O. Robledo, L.M. Gutierrez Baldivieso, V. Willis, D.R. Atri, A. Bateman, R.J. Ousset, P-J. Vellas, B. Weiner, M. |
| author_sort | Angioni, D. |
| collection | PubMed |
| description | Timely and accurate diagnosis of Alzheimer’s disease (AD) in clinical practice remains challenging. PET and CSF biomarkers are the most widely used biomarkers to aid diagnosis in clinical research but present limitations for clinical practice (i.e., cost, accessibility). Emerging blood-based markers have the potential to be accurate, cost-effective, and easily accessible for widespread clinical use, and could facilitate timely diagnosis. The EU/US CTAD Task Force met in May 2022 in a virtual meeting to discuss pathways to implementation of blood-based markers in clinical practice. Specifically, the CTAD Task Force assessed: the state-of-art for blood-based markers, the current use of blood-based markers in clinical trials, the potential use of blood-based markers in clinical practice, the current challenges with blood-based markers, and the next steps needed for broader adoption in clinical practice. |
| format | Online Article Text |
| id | pubmed-9683846 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-96838462023-01-01 Blood Biomarkers from Research Use to Clinical Practice: What Must Be Done? A Report from the EU/US CTAD Task Force Angioni, D. Delrieu, J. Hansson, O. Fillit, H. Aisen, P. Cummings, J. Sims, J.R. Braunstein, J.B. Sabbagh, M. Bittner, T. Pontecorvo, M. Bozeat, S. Dage, J.L. Largent, E. Mattke, S. Correa, O. Robledo, L.M. Gutierrez Baldivieso, V. Willis, D.R. Atri, A. Bateman, R.J. Ousset, P-J. Vellas, B. Weiner, M. J Prev Alzheimers Dis Article Timely and accurate diagnosis of Alzheimer’s disease (AD) in clinical practice remains challenging. PET and CSF biomarkers are the most widely used biomarkers to aid diagnosis in clinical research but present limitations for clinical practice (i.e., cost, accessibility). Emerging blood-based markers have the potential to be accurate, cost-effective, and easily accessible for widespread clinical use, and could facilitate timely diagnosis. The EU/US CTAD Task Force met in May 2022 in a virtual meeting to discuss pathways to implementation of blood-based markers in clinical practice. Specifically, the CTAD Task Force assessed: the state-of-art for blood-based markers, the current use of blood-based markers in clinical trials, the potential use of blood-based markers in clinical practice, the current challenges with blood-based markers, and the next steps needed for broader adoption in clinical practice. 2022 /pmc/articles/PMC9683846/ /pubmed/36281661 http://dx.doi.org/10.14283/jpad.2022.85 Text en https://creativecommons.org/licenses/by/4.0/Open Access: This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made. |
| spellingShingle | Article Angioni, D. Delrieu, J. Hansson, O. Fillit, H. Aisen, P. Cummings, J. Sims, J.R. Braunstein, J.B. Sabbagh, M. Bittner, T. Pontecorvo, M. Bozeat, S. Dage, J.L. Largent, E. Mattke, S. Correa, O. Robledo, L.M. Gutierrez Baldivieso, V. Willis, D.R. Atri, A. Bateman, R.J. Ousset, P-J. Vellas, B. Weiner, M. Blood Biomarkers from Research Use to Clinical Practice: What Must Be Done? A Report from the EU/US CTAD Task Force |
| title | Blood Biomarkers from Research Use to Clinical Practice: What Must Be Done? A Report from the EU/US CTAD Task Force |
| title_full | Blood Biomarkers from Research Use to Clinical Practice: What Must Be Done? A Report from the EU/US CTAD Task Force |
| title_fullStr | Blood Biomarkers from Research Use to Clinical Practice: What Must Be Done? A Report from the EU/US CTAD Task Force |
| title_full_unstemmed | Blood Biomarkers from Research Use to Clinical Practice: What Must Be Done? A Report from the EU/US CTAD Task Force |
| title_short | Blood Biomarkers from Research Use to Clinical Practice: What Must Be Done? A Report from the EU/US CTAD Task Force |
| title_sort | blood biomarkers from research use to clinical practice: what must be done? a report from the eu/us ctad task force |
| topic | Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9683846/ https://www.ncbi.nlm.nih.gov/pubmed/36281661 http://dx.doi.org/10.14283/jpad.2022.85 |
| work_keys_str_mv | AT angionid bloodbiomarkersfromresearchusetoclinicalpracticewhatmustbedoneareportfromtheeuusctadtaskforce AT delrieuj bloodbiomarkersfromresearchusetoclinicalpracticewhatmustbedoneareportfromtheeuusctadtaskforce AT hanssono bloodbiomarkersfromresearchusetoclinicalpracticewhatmustbedoneareportfromtheeuusctadtaskforce AT fillith bloodbiomarkersfromresearchusetoclinicalpracticewhatmustbedoneareportfromtheeuusctadtaskforce AT aisenp bloodbiomarkersfromresearchusetoclinicalpracticewhatmustbedoneareportfromtheeuusctadtaskforce AT cummingsj bloodbiomarkersfromresearchusetoclinicalpracticewhatmustbedoneareportfromtheeuusctadtaskforce AT simsjr bloodbiomarkersfromresearchusetoclinicalpracticewhatmustbedoneareportfromtheeuusctadtaskforce AT braunsteinjb bloodbiomarkersfromresearchusetoclinicalpracticewhatmustbedoneareportfromtheeuusctadtaskforce AT sabbaghm bloodbiomarkersfromresearchusetoclinicalpracticewhatmustbedoneareportfromtheeuusctadtaskforce AT bittnert bloodbiomarkersfromresearchusetoclinicalpracticewhatmustbedoneareportfromtheeuusctadtaskforce AT pontecorvom bloodbiomarkersfromresearchusetoclinicalpracticewhatmustbedoneareportfromtheeuusctadtaskforce AT bozeats bloodbiomarkersfromresearchusetoclinicalpracticewhatmustbedoneareportfromtheeuusctadtaskforce AT dagejl bloodbiomarkersfromresearchusetoclinicalpracticewhatmustbedoneareportfromtheeuusctadtaskforce AT largente bloodbiomarkersfromresearchusetoclinicalpracticewhatmustbedoneareportfromtheeuusctadtaskforce AT mattkes bloodbiomarkersfromresearchusetoclinicalpracticewhatmustbedoneareportfromtheeuusctadtaskforce AT correao bloodbiomarkersfromresearchusetoclinicalpracticewhatmustbedoneareportfromtheeuusctadtaskforce AT robledolmgutierrez bloodbiomarkersfromresearchusetoclinicalpracticewhatmustbedoneareportfromtheeuusctadtaskforce AT baldiviesov bloodbiomarkersfromresearchusetoclinicalpracticewhatmustbedoneareportfromtheeuusctadtaskforce AT willisdr bloodbiomarkersfromresearchusetoclinicalpracticewhatmustbedoneareportfromtheeuusctadtaskforce AT atria bloodbiomarkersfromresearchusetoclinicalpracticewhatmustbedoneareportfromtheeuusctadtaskforce AT batemanrj bloodbiomarkersfromresearchusetoclinicalpracticewhatmustbedoneareportfromtheeuusctadtaskforce AT oussetpj bloodbiomarkersfromresearchusetoclinicalpracticewhatmustbedoneareportfromtheeuusctadtaskforce AT vellasb bloodbiomarkersfromresearchusetoclinicalpracticewhatmustbedoneareportfromtheeuusctadtaskforce AT weinerm bloodbiomarkersfromresearchusetoclinicalpracticewhatmustbedoneareportfromtheeuusctadtaskforce AT bloodbiomarkersfromresearchusetoclinicalpracticewhatmustbedoneareportfromtheeuusctadtaskforce |